{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:25:31Z","timestamp":1787797531048,"version":"build-2784847793"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7918-26","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:10:26Z","timestamp":1784931026000},"source":"Crossref","is-referenced-by-count":2,"title":["Hyperuricemia in Chronic Kidney Disease: Clinical Evidence and the Missing Role of Urinary Uric Acid Handling"],"prefix":"10.2169","author":[{"given":"Tomoaki","family":"Takata","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Hisatome","sequence":"additional","affiliation":[{"name":"Matsue City Hospital, Japan"},{"name":"National Hospital Organization, Yonago Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Isomoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Sofue T, Nakagawa N, Kanda E, et al. Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: a nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLOS One 15: e0240402, 2020.","DOI":"10.1371\/journal.pone.0240402"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol 77: 323-345, 2015.","DOI":"10.1146\/annurev-physiol-021113-170343"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Takata T, Mae Y, Hoi S, Iyama T, Isomoto H. Hyperuricemia in chronic kidney disease: emerging pathophysiology and a novel therapeutic strategy. Int J Mol Sci 26: 9000, 2025.","DOI":"10.3390\/ijms26189000"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282: F991-F997, 2002.","DOI":"10.1152\/ajprenal.00283.2001"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kohagura K, Kochi M, Miyagi T, et al. An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res 36: 43-49, 2013.","DOI":"10.1038\/hr.2012.135"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sofue T. Hyperuricemia: the third key player for nephrosclerosis with ischemia. Hypertens Res 46: 1707-1709, 2023.","DOI":"10.1038\/s41440-023-01294-y"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med 382: 2504-2513, 2020.","DOI":"10.1056\/NEJMoa1915833"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Doria A, Galecki AT, Spino C, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med 382: 2493-2503, 2020.","DOI":"10.1056\/NEJMoa1916624"},{"key":"9","unstructured":"9. Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with Stage 3 CKD and asymptomatic hyperuricemia: A randomized trial. Am J Kidney Dis 72: 798-810, 2018."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of Chronic Kidney Disease. Kidney Int 105: S117-S314, 2024.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3: 764, 2012.","DOI":"10.1038\/ncomms1756"},{"key":"12","unstructured":"12. Hisatome I, Ichida K, Mineo I, et al. Japanese Society of Gout and Uric &amp; Nucleic Acids 2019 Guidelines for Management of Hyperuricemia and Gout. 3rd ed. Gout Uric Nucleic Acid 44: sp1-sp40, 2020."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Takata T, Mae Y, Hoi S, Hisatome I, Isomoto H. Redefining hyperuricemia in chronic kidney disease: a focus on tubulo-glomerular urate handling. Hypertens Res  48: 2766-2767, 2025.","DOI":"10.1038\/s41440-025-02311-y"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Wen S, Arakawa H, Tamai I. Uric acid in health and disease: from physiological functions to pathogenic mechanisms. Pharmacol Ther 256: 108615, 2024.","DOI":"10.1016\/j.pharmthera.2024.108615"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Takata T, Isomoto H. Back to the physiology: renal tubular handling of uric acid and emerging strategies for managing hyperuricemia. Intern Med 65: 520-525, 2026.","DOI":"10.2169\/internalmedicine.5926-25"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Siu YP, Leung KT, Tong MKH, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47: 51-59, 2006.","DOI":"10.1053\/j.ajkd.2005.10.006"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5: 1388-1393, 2010.","DOI":"10.2215\/CJN.01580210"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: A 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 66: 945-950, 2015.","DOI":"10.1053\/j.ajkd.2015.05.017"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yamamoto T, Kasahara M, Ueshima K, et al. Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET\u2013UA. Clin Exp Nephrol 28: 764-772, 2024.","DOI":"10.1007\/s10157-024-02483-w"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Stack AG, Dronamraju N, Parkinson J, et al. Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: a randomized trial. Am J Kidney Dis 77: 481-489, 2021.","DOI":"10.1053\/j.ajkd.2020.09.009"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Heerspink HJL, Stack AG, Terkeltaub R, et al. Combination treatment with verinurad and allopurinol in CKD: A randomized placebo and active controlled trial. J Am Soc Nephrol 35: 594-606, 2024.","DOI":"10.1681\/ASN.0000000000000326"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Amano H, Kobayashi S, Terawaki H. Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease. BMC Nephrol 25: 97, 2024.","DOI":"10.1186\/s12882-024-03535-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Takata T, Taniguchi S, Mae Y, et al. Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia. Sci Rep 15: 8990, 2025.","DOI":"10.1038\/s41598-025-94020-2"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Wang Y, Dalbeth N, Terkeltaub R, et al. Target serum urate achievement and chronic kidney disease progression in patients with gout and kidney disease. JAMA Intern Med  185: 74-82, 2025.","DOI":"10.1001\/jamainternmed.2024.6212"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ghang B, Park J, Lee JS, et al. Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy. Kidney Int 107: 521-529, 2025.","DOI":"10.1016\/j.kint.2024.10.022"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Cab\u0103u G, Cri\u0219an TO, Kl\u00fcck V, Popp RA, Joosten LAB. Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia. Immunol Rev 294: 92-105, 2020.","DOI":"10.1111\/imr.12833"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Cipolletta E, Nakafero G, McCormick N, et al. Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data. Lancet Rheumatol 7: e197-e207, 2025.","DOI":"10.1016\/S2665-9913(24)00248-0"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ohta Y, Ishizuka A, Arima H, et al. Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia. Hypertens Res 40: 259-263, 2017.","DOI":"10.1038\/hr.2016.139"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Asahina Y, Sakaguchi Y, Oka T, et al. Association between urinary uric acid excretion and kidney outcome in patients with CKD. Sci Rep 14: 5119, 2024.","DOI":"10.1038\/s41598-024-55809-9"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. L\u00f3pez Iglesias A, Blanco Pardo M, Rodr\u00edguez Magari\u00f1os C, et al. Association of urinary excretion rates of uric acid with biomarkers of kidney injury in patients with advanced chronic kidney disease. PLoS One 19: e0304105, 2024.","DOI":"10.1371\/journal.pone.0304105"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7918-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:26:06Z","timestamp":1784949966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7918-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":30,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7918-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7918-26"}}